Tagged with EU

Switzerland Aspen’s European Head Thomas Kerscher explains how the sale of the company’s thrombosis portfolio to Mylan has led to an organisational transformation in Europe with a leaner approach and an exclusive focus on anaesthesia. Kerscher also outlines the South African company’s response to the COVID-19 pandemic amid skyrocketing demand for…

Europe Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), shares the goals of his presidency and the role of the innovative European pharma industry in building a healthier future for the continent’s citizens in the wake of the COVID-19 pandemic.…

UK Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA, and his take on moving CAR-T cells to an earlier line of therapy.   We are calling strongly for a…

Ireland The Top 10 pharma companies in Ireland, ranked by annual turnover in The Irish Times Top 1000 list for 2021. Dublin-headquartered Allergan tops the list, followed by global giants MSD, Pfizer, and Gilead. Made with Visme Infographic Maker

Switzerland A. Vogel CEO Dr Andy Suter outlines the Swiss herbal medicine market leader’s expansion in recent years, why it is prioritising R&D more than ever, and how the COVID-19 pandemic has created a renewed focus on phytopharmaceuticals and preventive medicine.   There is a segment of people looking to take…

Denmark Novo Nordisk, Lundbeck, and LEO Pharma are the major players in the Danish pharmaceutical industry, all with significant R&D and manufacturing operations in the country. Made with Visme Infographic Maker Made with Visme Infographic Maker   Moreover, Denmark is the Nordics’ leading exporter of pharmaceuticals, as the below charts show. Made with Visme…

Europe Jasper Kunow, MSD’s managing director for Central Eastern Europe, outlines the threat that cancer still poses to Europe, the challenges of enacting the EU’s Beating Cancer Plan across the CEE region, and how policymakers and payers can help overcome them   “In 2020, while we were all fighting against the…

Denmark On April 16, the Danish government unveiled, to great anticipation and fanfare, a brand-new National Life Science Strategy which seeks to chart the course for the next three years of an industry sector that has become increasingly influential for the country’s economy. Indeed, Denmark’s healthcare and life sciences segment now…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…

Switzerland While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland is increasingly tightening its belt on this front in line with its European neighbours. Indeed, this year two cost containment packages are under discussion in the Swiss parliament…

Switzerland Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique transcription factor targeting molecule potentially represents a breakthrough in cancer research, the ways in which the firm’s funding strategy has evolved, and how its future growth trajectory might look.…

Switzerland Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the presence of Roche, Novartis, Lonza and many others; explains why biotech companies are choosing to go public at later stages…